FR3017297A1 - Composition pharmaceutique pour le traitement de la dependance chez l'etre humain - Google Patents
Composition pharmaceutique pour le traitement de la dependance chez l'etre humain Download PDFInfo
- Publication number
- FR3017297A1 FR3017297A1 FR1400401A FR1400401A FR3017297A1 FR 3017297 A1 FR3017297 A1 FR 3017297A1 FR 1400401 A FR1400401 A FR 1400401A FR 1400401 A FR1400401 A FR 1400401A FR 3017297 A1 FR3017297 A1 FR 3017297A1
- Authority
- FR
- France
- Prior art keywords
- dependence
- pharmaceutical composition
- nic
- lorcaserine
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 37
- 238000011282 treatment Methods 0.000 title claims abstract description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims abstract description 23
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims abstract description 23
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 claims abstract description 22
- 230000003042 antagnostic effect Effects 0.000 claims abstract description 22
- 229960001289 prazosin Drugs 0.000 claims abstract description 22
- 229960002613 tamsulosin Drugs 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960001389 doxazosin Drugs 0.000 claims abstract description 21
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229960001693 terazosin Drugs 0.000 claims abstract description 21
- 229960004607 alfuzosin Drugs 0.000 claims abstract description 20
- 230000009471 action Effects 0.000 claims abstract description 11
- 239000000556 agonist Substances 0.000 claims abstract description 9
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 claims description 14
- 229960004953 silodosin Drugs 0.000 claims description 14
- 206010012335 Dependence Diseases 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 9
- 230000003236 psychic effect Effects 0.000 claims description 9
- 230000002295 serotoninergic effect Effects 0.000 claims description 9
- 230000003542 behavioural effect Effects 0.000 claims description 7
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- -1 allivosin Chemical compound 0.000 claims description 4
- 239000013066 combination product Substances 0.000 claims description 4
- 229940127555 combination product Drugs 0.000 claims description 4
- 206010034158 Pathological gambling Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 230000002474 noradrenergic effect Effects 0.000 claims description 2
- CXENHBSYCFFKJS-OXYODPPFSA-N (Z,E)-alpha-farnesene Chemical compound CC(C)=CCC\C(C)=C\C\C=C(\C)C=C CXENHBSYCFFKJS-OXYODPPFSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 abstract description 22
- 108020003175 receptors Proteins 0.000 abstract description 22
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 abstract description 7
- 108091005479 5-HT2 receptors Proteins 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 20
- 239000000047 product Substances 0.000 description 16
- 239000000203 mixture Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 230000006742 locomotor activity Effects 0.000 description 7
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 6
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 241000208125 Nicotiana Species 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 229940025084 amphetamine Drugs 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 229960000632 dexamfetamine Drugs 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229960002715 nicotine Drugs 0.000 description 4
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 description 3
- 239000000674 adrenergic antagonist Substances 0.000 description 3
- 201000007930 alcohol dependence Diseases 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 3
- 230000000848 glutamatergic effect Effects 0.000 description 3
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 3
- 229960003086 naltrexone Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000003368 psychostimulant agent Substances 0.000 description 3
- DVQGVNABCBCXBX-UHFFFAOYSA-N 2,3-dihydro-1h-indole-7-carboxamide Chemical compound NC(=O)C1=CC=CC2=C1NCC2 DVQGVNABCBCXBX-UHFFFAOYSA-N 0.000 description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010052804 Drug tolerance Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920005372 Plexiglas® Polymers 0.000 description 2
- 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000026781 habituation Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 208000024335 physical disease Diseases 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 101150035983 str1 gene Proteins 0.000 description 2
- NZMOFYDMGFQZLS-UHFFFAOYSA-N terazosin hydrochloride dihydrate Chemical compound [H+].O.O.[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 NZMOFYDMGFQZLS-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- QRMWZDWSESEBSD-UHFFFAOYSA-N CCOC1=CC=CC=C1OCCNCCCC2=C(C(=CC=C2)S(=O)(=O)N)OC Chemical compound CCOC1=CC=CC=C1OCCNCCCC2=C(C(=CC=C2)S(=O)(=O)N)OC QRMWZDWSESEBSD-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000003698 Heroin Dependence Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000025569 Tobacco Use disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010060953 Ventricular failure Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 1
- 229960004047 acamprosate Drugs 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 229940120049 belviq Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960003998 ifenprodil Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- WRZCAWKMTLRWPR-VSODYHHCSA-N lorcaserin hydrochloride hemihydrate Chemical compound O.Cl.Cl.C[C@H]1CNCCC2=CC=C(Cl)C=C12.C[C@H]1CNCCC2=CC=C(Cl)C=C12 WRZCAWKMTLRWPR-VSODYHHCSA-N 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229940064639 minipress Drugs 0.000 description 1
- 229960005297 nalmefene Drugs 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- GXHAENUAJYZNOA-UHFFFAOYSA-N oxolane-2-carboxamide Chemical compound NC(=O)C1CCCO1 GXHAENUAJYZNOA-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960004751 varenicline Drugs 0.000 description 1
- TWYFGYXQSYOKLK-CYUSMAIQSA-N varenicline tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C12=CC3=NC=CN=C3C=C2[C@H]2C[C@@H]1CNC2 TWYFGYXQSYOKLK-CYUSMAIQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
- REVENDICATIONS1. Composition pharmaceutique pour le traitement de la dépendance chez l'être 5 humain comprenant deux principes actifs : un composé ayant une action agoniste sur les récepteurs 5-1-11-2 sérotoninergiques choisi comme étant la lorcaserine ; et un composé ayant une action antagoniste sur les récepteurs alph.a1. noradrénergiques choisi parmi la prazosine, l'allivosine, la térazosine, la 10 tamsulosine, la silodosine et la doxazosine..
- 2. Composition pharmaceutique selon la reven.dication. 1. caractérisée en ce qu'elle comprend : de 0,02 à 50 mg de lorcaserine; et 15 - de 0,025 à 20 mg de prazosine, de 0,075 à 10 mg d'alfuzosine, de 0,01 à 5 mg de térazosine, de 0,004 à 0,4 mg de tamsulosine, de 0,05 à. 30 mg de silodosine, ou de 0,025 à 10 mg de doxazosine.
- 3. Composition pharmaceutique selon la revendication 1 ou 2, caractérisée en ce 20 que le composé ayant une action antagoniste sur les récepteurs alphal-noradrénergiques est choisi parmi la prazosine, l'alfuzosine, la térazosine, la silodosine, la doxazosine et la tamsulosine.
- 4.. Composition pharmaceutique selon la revendication 3, caractérisée en ce que le 25 composé ayant une action antagoniste sur les récepteurs alphal-noradrénergiques est la prazosine.
- 5. Composition pharmaceutique selon la revendication 2, caractérisée en ce qu'elle est administrable au patient en état de dépendance selon une dose de lorcasérine 30 comprise entre 0,02 et 200 mg. CONFIDENTIEL - rérsian re-.26/06/14De Greenpharma Thu Jun 26 16:38:53 2014 Page 3 sur 3 22
- 6. Composition pharmaceutique selon la revendication 2, caractérisée en ce qu'elle est administrable au patient en état de dépendance selon une dose de lorcasérine comprise entre 0,14 et 350 mg.
- 7. Composition pharmaceutique selon l'une des revendications 1 à. 6, caractérisée en ce que la dépendance est une dépendance physique.
- 8. Composition pharmaceutique selon l'une des revendications 1. à 7, caractérisée en ce que la dépendance est une dépendance psychique. 10 9, Composition pharmaceutique selon l'une des revendications 1 à 8, caractérisée en ce que la dépendance est une dépendance comportementale. 10. Composition pharmaceutique selon la revendication 9, caractérisée en ce que la 15 dépendance est une dépendance aux Jeux. 11. Produit pharmaceutique contenant : un composé ayant une action agoniste sur les récepteurs 5-11T2 sérotoninergiques choisi comme étant la lorcaserine ; et. 20 un composé ayant une action antagoniste sur les récepteurs alphal- noradrénergiques choisi parmi la prazosine, l'alfuzosine, la térazosine, la tamsulosine, la silodosine et la doxazosine; comme produit de combinaison pour une administration simultanée, séparée ou étalée dans le temps dans le cadre du traitement de la dépendance chez l'être humain.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1400401A FR3017297B1 (fr) | 2013-11-28 | 2014-02-12 | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1302800A FR3017296A1 (fr) | 2013-11-28 | 2013-11-28 | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
FR1302800 | 2013-11-28 | ||
FR1400401A FR3017297B1 (fr) | 2013-11-28 | 2014-02-12 | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3017297A1 true FR3017297A1 (fr) | 2015-08-14 |
FR3017297B1 FR3017297B1 (fr) | 2018-03-30 |
Family
ID=51167955
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1302800A Pending FR3017296A1 (fr) | 2013-11-28 | 2013-11-28 | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
FR1400401A Expired - Fee Related FR3017297B1 (fr) | 2013-11-28 | 2014-02-12 | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR1302800A Pending FR3017296A1 (fr) | 2013-11-28 | 2013-11-28 | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
Country Status (1)
Country | Link |
---|---|
FR (2) | FR3017296A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016069875A1 (fr) * | 2014-10-30 | 2016-05-06 | Arena Pharmaceuticals, Inc. | Compositions et procédés permettant de renoncer au tabac |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012175894A1 (fr) * | 2011-06-24 | 2012-12-27 | Greenpharma | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
-
2013
- 2013-11-28 FR FR1302800A patent/FR3017296A1/fr active Pending
-
2014
- 2014-02-12 FR FR1400401A patent/FR3017297B1/fr not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012175894A1 (fr) * | 2011-06-24 | 2012-12-27 | Greenpharma | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain |
Non-Patent Citations (1)
Title |
---|
GUY A HIGGINS ET AL: "The 5-HT2C Receptor Agonist Lorcaserin Reduces Nicotine Self-Administration, Discrimination, and Reinstatement: Relationship to Feeding Behavior and Impulse Control", NEUROPSYCHOPHARMACOLOGY, vol. 37, no. 5, 21 December 2011 (2011-12-21), pages 1177 - 1191, XP055141024, ISSN: 0893-133X, DOI: 10.1038/npp.2011.303 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016069875A1 (fr) * | 2014-10-30 | 2016-05-06 | Arena Pharmaceuticals, Inc. | Compositions et procédés permettant de renoncer au tabac |
Also Published As
Publication number | Publication date |
---|---|
FR3017297B1 (fr) | 2018-03-30 |
FR3017296A1 (fr) | 2015-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2618212C (fr) | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte et son application therapeutique | |
EP1773306A1 (fr) | Medicament destine au traitement des desordres du systeme nerveux central | |
CH702775B1 (fr) | Pastilles de gélatine douces contenant de la nicotine et procédé de préparation. | |
JP6163289B2 (ja) | 嗜癖の予防および治療のための組成物および方法 | |
US10064850B2 (en) | Compositions and methods for prophylaxis and treatment of addictions | |
FR2530469A1 (fr) | Composition analgesique et anti-inflammatoire contenant de la cafeine | |
EP2293790A2 (fr) | Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition pharmaceutique la contenant et son utilisation dans le traitement des troubles cognitifs | |
EP2519233B1 (fr) | Composition pharmaceutique pour le traitement de la dépendance à l'alcool | |
Waters | Pharmacologic similarities and differences among hallucinogens | |
WO2012175894A1 (fr) | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain | |
FR3017297A1 (fr) | Composition pharmaceutique pour le traitement de la dependance chez l'etre humain | |
Kukuia et al. | Antidepressant effects of mallotus oppositifolius in acute murine models | |
RU2461374C1 (ru) | Биологически активное средство, влияющее на общеметаболические, возбуждающие и тормозные функции нервной системы и интеллектуально-мнестические функции головного мозга (варианты) | |
US11241420B2 (en) | Compositions and methods for prophylaxis and treatment of addictions | |
SHAPIRO | Ibogaine: History, Pharmacology, Spirituality, & Clinical Data | |
EP1827495B1 (fr) | Associations anti-douleur comprenant un derive de dihydroimidazopyrazine | |
EP2258354B1 (fr) | Composés et méthodes pour contrôler la prise d'alcool. | |
EP2252278B1 (fr) | Agonistes béta-2 adrénergiques pour utilisation dans le traitement de l'allodynie neuropathique chronique | |
FR2937552A1 (fr) | Composition pharmaceutique destinee a la prevention ou au traitement du syndrome de sevrage alcoolique | |
FR2926464A1 (fr) | Composes utilisables pour le traitement de douleurs neuropathiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |
|
PLFP | Fee payment |
Year of fee payment: 7 |
|
ST | Notification of lapse |
Effective date: 20191006 |
|
RN | Application for restoration |
Effective date: 20191025 |
|
FC | Decision of inpi director general to approve request for restoration |
Effective date: 20200107 |
|
PLFP | Fee payment |
Year of fee payment: 9 |
|
ST | Notification of lapse |
Effective date: 20211005 |
|
RN | Application for restoration |
Effective date: 20211012 |
|
RN | Application for restoration |
Effective date: 20211021 |
|
FC | Decision of inpi director general to approve request for restoration |
Effective date: 20211207 |
|
PLFP | Fee payment |
Year of fee payment: 10 |
|
PLFP | Fee payment |
Year of fee payment: 11 |